As we await an #ADAURA update at #ASCO24, this survey Clinical Lung Cancer explores patient preferences for adjuvant osimertinib after resection of #EGFR NSCLC. For most, DFS was sufficient, but cost is a major issue: 33% would not pay even with an OS benefit. clinical-lung-cancer.com/article/S1525-…

Impact of anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: a CCC19 registry analysis [Apr 10, 2024] Kulkarni et al. Narjust Florez, MD, FASCO COVID-19 and Cancer Consortium (CCC19) Registry Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-… #COVID19nCancer #COVID19 #lcsm

Design of FOCUS-C trial Clinical Lung Cancer. Pts w/ #EGFR mutant NSCLC receive 3G EGFR TKI furmonertinib. If ctDNA clears, continue TKI. If not, randomized to TKI alone, TKI + carbo/pem, or TKI + carbo/pem/bev. NCT05334277. Similar to study from Helena Yu. clinical-lung-cancer.com/article/S1525-…

Impact of anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: a CCC19 registry analysis [Apr 10, 2024] Kulkarni et al. Narjust Florez, MD, FASCO COVID-19 and Cancer Consortium (CCC19) Registry Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-… #COVID19nCancer #COVID19 #lcsm

Retrospective report Clinical Lung Cancer shows elevated neutrophil:lymphocyte ratio associated with lower survival from start of immunotherapy - for those with and without EGFR, ALK, or ROS1 alterations. clinical-lung-cancer.com/article/S1525-…

Retrospective look at impact of durvalumab on pneumonitis after chemoradiation for NSCLC Clinical Lung Cancer. With durva, 57% G1 pneumonitis, 38% G2, 5% G3. Steroid course 17w with durva and 7w without. Pneumonitis relapse 23% with durvalumab, 7% without. clinical-lung-cancer.com/article/S1525-…

Real world data on QTc prolongation with osimertinib Clinical Lung Cancer. 970 pts with #EGFR NSCLC & pre/post EKGs: 0.9% had G3 QTc prolongation (median onset d49) with no arrhythmic events; most had baseline QTc>450. Rechallenge better with dose reduction. clinical-lung-cancer.com/article/S1525-…

Real world outcomes with durvalumab after chemoradiation for stage III NSCLC (PACIFIC) in an elderly population (age ≥75y) Clinical Lung Cancer. No significant difference in PFS or irAEs between older and younger groups. Overall consistent outcomes with trial. clinical-lung-cancer.com/article/S1525-…

Can we predict risk of immune related toxicity with immunotherapy for NSCLC? Report Clinical Lung Cancer showed 15.2% rate of high-grade irAEs overall (esp respiratory and GI) with higher risk seen with mutations in MYC, TEK, FANCA, FAM123B, MET. clinical-lung-cancer.com/article/S1525-…

PD-L1 & outcomes from consolidation durvalumab after chemoradiation for stage III NSCLC in Netherlands Cancer Registry Clinical Lung Cancer. From 2017 to 2021, use of PACIFIC increased from 2% to 62%. 4y OS 67% for PDL1 high, 46% for low, 51% for negative. clinical-lung-cancer.com/article/S1525-…

Real world outcomes with chemotherapy for pts who progress after PACIFIC regimen (durvalumab after chemoradiation for stage III NSCLC) Clinical Lung Cancer. Platinum based chemotherapy had PFS 13.2m if durvalumab PFS ≥1y but only 4.7m if durva PFS < 1y. clinical-lung-cancer.com/article/S1525-…

More on RBM10 and NSCLC at Clinical Lung Cancer. Associated with worse prognosis (PFS 6.7m vs 13.9m) and with TP53 co-mutation, more likely to have rapid progression. Recall RBM10 seen in residual disease after neoadjuvant EGFR TKI in work from Collin Blakely MD, PhD. clinical-lung-cancer.com/article/S1525-…

Description of long-term outcomes from immunotherapy-related pneumonitis in NSCLC Clinical Lung Cancer. Non-adenocarcinoma, grade 3 severity, and only partial radiological resolution associated with ongoing pulmonary symptoms. clinical-lung-cancer.com/article/S1525-…

Explore a multicenter real-world analysis highlighting the clinical activity of combined MET and EGFR inhibition in NSCLC after EGFR inhibitor therapy, suggesting that true MET amplification, rather than polysomy, is associated with clinical benefit. bit.ly/4di4pHT

🔥Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy 🎙️Dr. Saori Murata Hidehito HORINOUCHI Clinical Lung Cancer 🎯Duration📈 🎯Complexity of tapering patterns📈 #LCSM OncoAlert clinical-lung-cancer.com/article/S1525-…

Can an electronic medical record (EMR) alert really increase uptake of lung cancer screening? Report Clinical Lung Cancer shows screening increased from 2.2% of eligible patients to 21.1% with higher rates for age ≥ 65 (25.8%) vs younger (15.6%). clinical-lung-cancer.com/article/S1525-…

Screening 4 lung cancer increased from 2.2% of eligible patients to 21.1% w/ higher rates for age ≥ 65 (25.8%) vs younger (15.6%) when electronic medical record/EMR alert was implemented said Inova researchers' report Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-… h/t Stephen V Liu, MD #lcsm

Clinical Lung Cancer 🫁 Pembrolizumab monotherapy regimen in PD-L1 Expression ≥ 50% Advanced NSCLC. 🫁 Large-scale 5-year real-world study. (n=804) Vamsi Velcheti, MD MBA FASCO Dr. Vamsidhar Velcheti Stephen V Liu, MD #Pembrolizumab #NSCLC #ICI #LCSM

While amylase & lipase elevation often seen in trials of targeted agents, actual clinical pancreatitis is uncommon. In this retrospective report Clinical Lung Cancer from Drs. Meyer May-Lucie Mihaela Aldea and team, incidence of clinical pancreatitis was .08%! clinical-lung-cancer.com/article/S1525-…

Second primary lung cancer among patients with a history of breast cancer is strongly associated with smoking, in report Clinical Lung Cancer. 24% increased risk for every 10 smoking pack years. But most would not be eligible for lung cancer screening. clinical-lung-cancer.com/article/S1525-…